Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Upgrade Now
NasdaqGM - Nasdaq Real Time Price USD

Aurinia Pharmaceuticals Inc. (AUPH)

Compare
8.05
-0.14
(-1.71%)
At close: April 3 at 4:00:02 PM EDT
8.06
+0.01
+(0.12%)
Pre-Market: 4:28:23 AM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
235,133
235,133
175,513
134,030
45,605
Cost of Revenue
28,248
28,248
14,148
5,664
1,091
Gross Profit
206,885
206,885
161,365
128,366
44,514
Operating Expense
188,466
188,466
253,056
239,836
225,249
Operating Income
18,419
18,419
-91,691
-111,470
-180,735
Net Non Operating Interest Income Expense
12,135
12,135
14,222
5,118
529
Other Income Expense
-23,106
-23,106
--
--
--
Pretax Income
7,448
7,448
-77,469
-106,352
-180,206
Tax Provision
1,696
1,696
551
1,828
760
Net Income Common Stockholders
5,752
5,752
-78,020
-108,180
-180,966
Diluted NI Available to Com Stockholders
5,752
5,752
-78,020
-108,180
-180,966
Basic EPS
-0.15
0.04
-0.54
-0.76
-1.40
Diluted EPS
-0.15
0.04
-0.54
-0.76
-1.40
Basic Average Shares
143,437
143,057
143,236
141,915
129,369
Diluted Average Shares
144,679.75
146,194
143,236
141,915
129,369
Total Operating Income as Reported
-4,687
-4,687
-91,691
-111,470
-180,735
Total Expenses
216,714
216,714
267,204
245,500
226,340
Net Income from Continuing & Discontinued Operation
5,752
5,752
-78,020
-108,180
-180,966
Normalized Income
23,589.83
23,589.83
-78,020
-108,180
-180,966
Interest Income
16,970
16,970
16,997
5,118
529
Interest Expense
4,835
4,835
2,775
--
--
Net Interest Income
12,135
12,135
14,222
5,118
529
EBIT
12,283
12,283
-74,694
-106,352
-180,206
EBITDA
31,728
31,728
-63,047
-103,646
-177,445
Reconciled Cost of Revenue
28,248
28,248
14,148
5,664
1,091
Reconciled Depreciation
19,445
19,445
11,647
2,706
2,761
Net Income from Continuing Operation Net Minority Interest
5,752
5,752
-78,020
-108,180
-180,966
Total Unusual Items Excluding Goodwill
-23,106
-23,106
--
--
--
Total Unusual Items
-23,106
-23,106
--
--
--
Normalized EBITDA
54,834
54,834
-63,047
-103,646
-177,445
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-5,268.17
-5,268.17
--
--
--
12/31/2021 - 9/3/2014

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

TGTX TG Therapeutics, Inc.
39.34
-1.21%
 
AXSM Axsome Therapeutics, Inc.
107.89
-1.69%
 
FOLD Amicus Therapeutics, Inc.
8.00
+0.13%
 
INCY Incyte Corporation
62.46
+0.21%
 
APLS Apellis Pharmaceuticals, Inc.
22.52
-2.09%
 
VRNA Verona Pharma plc
58.09
-3.65%
 
SWTX SpringWorks Therapeutics, Inc.
43.07
-7.42%
 
TVTX Travere Therapeutics, Inc.
16.56
-7.69%
 
KPTI Karyopharm Therapeutics Inc.
3.8600
-4.93%
 
EWTX Edgewise Therapeutics, Inc.
13.58
-12.50%